ArticleInternational journal of obesity (2005)2019
Rosiglitazone reverses high fat diet-induced changes in BMAL1 function in muscle, fat, and liver tissue in mice.
Article in International journal of obesity (2005), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 18 citations in OpenAlex.
- [Interactions among circadian rhythm, obesity, and inflammation and their regulation by exercise].Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2026Review
- Time-restricted feeding in rodent obesity models: impact on body weights, lipid profile and glucoregulation.International journal of obesity (2005) · 2026Review
- Chronic low-dose REV-ERBs agonist SR9009 mitigates constant light-induced weight gain and insulin resistance via adipogenesis modulation.Biomedical journal · 2025Article
- Regulation of circadian gene activity in fibroblasts from ADHD patients through Rosiglitazone: a pilot study.Journal of neural transmission (Vienna, Austria : 1996) · 2025Article
- Discovery of a selective dual-specificity tyrosine phosphorylation-regulated kinase 1B inhibitor with anti-adipogenic and anti-diabetic activities.Frontiers in pharmacology · 2025Article
- Extracellular Vesicles, Circadian Rhythms, and Cancer: A Comprehensive Review with Emphasis on Hepatocellular Carcinoma.Cancers · 2024Review
- Time-restricted eating, the clock ticking behind the scenes.Frontiers in pharmacology · 2024Review
- Review
- Nonalcoholic Steatohepatitis Disrupts Diurnal Liver Transcriptome Rhythms in Mice.Cellular and molecular gastroenterology and hepatology · 2023Article
- PPAR-PPAR research · 2022Article
- The Importance of Keeping Time in the Liver.Endocrinology · 2021Review
- Advances in Unhealthy Nutrition and Circadian Dysregulation in Pathophysiology of NAFLD.Frontiers in clinical diabetes and healthcare · 2021Review
- Review
- Off the Clock: From Circadian Disruption to Metabolic Disease.International journal of molecular sciences · 2019Review
- Interplay between diet, exercise and the molecular circadian clock in orchestrating metabolic adaptations of adipose tissue.The Journal of physiology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
Abstract
objectiveNutrient challenge in the form of a high fat (HF) diet causes a reversible reprogramming of the hepatic circadian clock. This depends in part on changes in the recruitment of the circadian transcription factor BMAL1 to genome targets, though the causes and extent of disruption to hepatic and extra-hepatic BMAL1 are unknown. The objective of the study was to determine whether HF diet-induced alterations in BMAL1 function occur across insulin-resistant tissues and whether this could be reversed by restoring whole body insulin sensitivity.
methodsBMAL1 subcellular localization and target recruitment was analyzed in several metabolically active peripheral tissues, including liver, muscle, and adipose tissue under conditions of diet-induced obesity. Animals made obese with HF diet were subsequently treated with rosiglitazone to determine whether resensitizing insulin-resistant tissues to insulin restored hepatic and extra-hepatic BMAL1 function.
resultsThese data reveal that both hepatic and extra-hepatic BMAL1 activity are altered under conditions of obesity and insulin resistance. Restoring whole body insulin sensitivity by treatment with the antidiabetic drug rosiglitazone is sufficient to restore changes in HF diet-induced BMAL1 recruitment and activity in several tissues.
conclusionsThis study reveals that a key mechanism by which HF diet interferes with clock function in peripheral tissues is via the development of insulin resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.